Signaling pathway-based identification of extensive prognostic gene signatures for lung adenocarcinoma

Lung Cancer

Volumn 76, Issue 1, 2012, Pages 98-105

  Wan, Ying Wooi ^a   Beer, David G ^b   Guo, Nancy Lan ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Biomarker identification; Gene co expression network; Lung adenocarcinoma; Metastasis; Non small cell lung cancer; Prognostic stratification; Signaling pathways; Tumor recurrence

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; ALGORITHM; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE SEVERITY; DISEASE SPECIFIC SURVIVAL; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC RISK; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; RACE; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SMOKING; TUMOR DIFFERENTIATION; TUMOR GENE;

ADENOCARCINOMA; ALGORITHMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84858008460     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.09.016     Document Type: Article

References (35)

1. Hoffman P.C., Mauer A.M., Vokes E.E. Lung cancer. Lancet 2000, 355(February (9202)):479-485.
2. Naruke T., Goya T., Tsuchiya R., Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988, 96(September (3)):440-447.
3. General thoracic surgery 2009, Lippincott Williams & Wilkins, Philadelphia. 7th ed.
4. Dalton W.S., Friend S.H. Cancer biomarkers - an invitation to the table. Science 2006, 312(May (5777)):1165-1168.
5. Subramanian J., Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use?. J Natl Cancer Inst 2010, 102(April (7)):464-474.
6. Beer D.G., Kardia S.L., Huang C.C., Giordano T.J., Levin A.M., Misek D.E., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002, 8(August (8)):816-824.
7. Bhattacharjee A., Richards W.G., Staunton J., Li C., Monti S., Vasa P., et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001, 98(November (24)):13790-13795.
8. Bild A.H., Yao G., Chang J.T., Wang Q., Potti A., Chasse D., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439(January (7074)):353-357.
9. Borczuk A.C., Kim H.K., Yegen H.A., Friedman R.A., Powell C.A. Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness. Am J Respir Crit Care Med 2005, 172(September (6)):729-737.
10. Chen H.Y., Yu S.L., Chen C.H., Chang G.C., Chen C.Y., Yuan A., et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007, 356(January (1)):11-20.
11. Raponi M., Zhang Y., Yu J., Chen G., Lee G., Taylor J.M., et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006, 66(August (15)):7466-7472.
12. Shedden K., Taylor J.M., Enkemann S.A., Tsao M.S., Yeatman T.J., Gerald W.L., et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008, 14(August (8)):822-827.
13. Baker S.G., Kramer B.S., Srivastava S. Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol 2002, 2:4.
14. Emir B., Wieand S., Su J.Q., Cha S. Analysis of repeated markers used to predict progression of cancer. Stat Med 1998, 17(November (22)):2563-2578.
15. Pepe M.S., Janes H., Longton G., Leisenring W., Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004, 159(May (9)):882-890.
16. Hartwell L.H., Hopfield J.J., Leibler S., Murray A.W. From molecular to modular cell biology. Nature 1999, 402(December (6761 Suppl.)):C47-C52.
17. Chuang H.Y., Lee E., Liu Y.T., Lee D., Ideker T. Network-based classification of breast cancer metastasis. Mol Syst Biol 2007, 3:140.
18. Csermely P., Agoston V., Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005, 26(April (4)):178-182.
19. Sotiriou C., Piccart M.J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev Cancer 2007, 7(July (7)):545-553.
20. Mani K.M., Lefebvre C., Wang K., Lim W.K., Basso K., la-Favera R., et al. A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas. Mol Syst Biol 2008, 4:169.
21. Cui Q., Ma Y., Jaramillo M., Bari H., Awan A., Yang S., et al. A map of human cancer signaling. Mol Syst Biol 2007, 3:152.
22. Li C. Automating dChip: toward reproducible sharing of microarray data analysis. BMC Bioinformatics 2008, 9:231.
23. Guo L., Cukic B., Singh H. Predicting fault prone modules by the Dempster-Shafer belief networks. Proceedings of 18th IEEE international conference on automated software engineering (ASE'03). 2003, 249-252.
24. Hildebrand D.K., Laing J.D., Rosenthal H. Prediction analysis of cross classifications 1977, John Wiley & Sons.
25. Guo N.L., Wan Y.W., Bose S., Denvir J., Kashon M.L., Andrew M.E. A novel network model identified a 13-gene lung cancer prognostic signature. Int J Comput Biol Drug Des 2011, 4(1):19-39.
26. Breiman L. Random forests. Mach Learn 2001, 45:5-32.
27. Diaz-Uriarte R., Alvarez dA. Gene selection and classification of microarray data using random forest. BMC Bioinformatics 2006, 7:3.
28. Hall M.A., Holmes G. Benchmarking attribute selection techniques for discrete class data mining. IEEE Trans Knowl Data Eng 2003, 15(3):1437-1447.
29. Witten I.H., Frank E. Data mining practical machine learning tools and techniques 2005, Morgan Kaufmann. 2nd edition.
30. Wan Y.W., Bose S., Denvir J., Guo N.L. A novel network model for molecular prognosis. Proceedings of ACM international conference on bioinformatics and computational biology 2010, 342-345.
31. Jones K.J., Korb E., Kundel M.A., Kochanek A.R., Kabraji S., McEvoy M., et al. CPEB1 regulates beta-catenin mRNA translation and cell migration in astrocytes. Glia 2008, 56(October (13)):1401-1413.
32. Burns D.M., Richter J.D. CPEB regulation of human cellular senescence, energy metabolism, and p53 mRNA translation. Genes Dev 2008, 22(December (24)):3449-3460.
33. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(January (6871)):530-536.
34. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347(December (25)):1999-2009.
35. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(December (27)):2817-2826.